Rapamycin /Everolimus
Rapamycin: one drug, many effects.
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
Rapamycin and Alzheimer's disease: Time for a clinical trial?
Fasting and rapamycin: diabetes versus benevolent glucose intolerance.
Is Rapamycin a Dietary Restriction Mimetic?
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Rapamycin in ischemic stroke: Old drug, new tricks?
The Enigma of Rapamycin Dosage.
Rapamycin and ageing: when, for how long, and how much?
Rapamycin-resistant effector T-cell therapy.
mTOR: a pharmacologic target for autophagy regulation.
Adrenoceptor regulation of the mechanistic target of rapamycin in muscle and adipose tissue.
Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.
From rapalogs to anti-aging formula.
From causes of aging to death from COVID-19.
Is there a role for immunosuppression in antiphospholipid syndrome?
Rapamycin and rapalogs for tuberous sclerosis complex.
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Longevity, aging and rapamycin.
Tuberous sclerosis complex: review based on new diagnostic criteria.
Toward rapamycin analog (rapalog)-based precision cancer therapy.
On the Discovery of TOR As the Target of Rapamycin.
Pathogenesis and management of antiphospholipid syndrome.
Paradoxical aspects of rapamycin immunobiology in transplantation.
Rapamycin: friend, foe, or misunderstood?
Rapalogs and mTOR inhibitors as anti-aging therapeutics.
Rapamycin in transplantation: a review of the evidence.
Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.
The mTOR signalling pathway in human cancer.
Towards a therapy for mitochondrial disease: an update.
Targeting mTOR with rapamycin: one dose does not fit all.
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Pulmonary manifestations in tuberous sclerosis complex.
mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
Roles of mTOR Signaling in Tissue Regeneration.
Rapamycin in islet transplantation: friend or foe?
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
mTOR-targeted therapy of cancer with rapamycin derivatives.
Everolimus and sirolimus in transplantation-related but different.
Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to.
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Mammalian target of rapamycin inhibitor-associated stomatitis.
Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
Autophagy and cardiovascular aging: lesson learned from rapamycin.
Systemic therapy in metastatic renal cell carcinoma.
Molecular signatures of longevity: Insights from cross-species comparative studies.
Mammalian target of rapamycin signaling in cardiac physiology and disease.
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells.
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.
Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.
Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism.
Frailty index as a biomarker of lifespan and healthspan: Focus on pharmacological interventions.
Protein translocation as a tool: The current rapamycin story.
Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae.
Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.
Potential use of rapamycin in HIV infection.
Liver transplant immunosuppression during the covid-19 pandemic.
The target of rapamycin (TOR) proteins.
Rheb and mammalian target of rapamycin in mitochondrial homoeostasis.
Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review.
Energy restriction in renal protection.
Mammalian target of rapamycin: a central node of complex signaling cascades.
The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.
Temsirolimus, an inhibitor of mammalian target of rapamycin.
Epstein-Barr virus, rapamycin, and host immune responses.
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Rapamycin for chemoprevention of upper aerodigestive tract cancers.
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.
Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
mTOR signaling in the differentiation and function of regulatory and effector T cells.
Next Generation Strategies for Geroprotection via mTORC1 Inhibition.
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Immunotherapy for metastatic renal cell carcinoma.
Targeting the mTOR pathway in breast cancer.
The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
Magmaris™ resorbable magnesium scaffold: state-of-art review.
Drugs that target aging: how do we discover them?
Crohn's Disease: Potential Drugs for Modulation of Autophagy.
Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Pharmacologic agents targeting autophagy.
Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
Medical therapy for polycystic liver disease.
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Architecture and activation of phosphatidylinositol 3-kinase related kinases.
Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
Determining sensitivity to rapamycin and its analogues in breast cancer patients.
Nutrition, metabolism, and targeting aging in nonhuman primates.
Koschei the immortal and anti-aging drugs.
Elucidation of the mTOR Pathway and Therapeutic Applications in Dermatology.
The role of mTOR in memory CD8 T-cell differentiation.
Role of mTOR Inhibitors in Kidney Disease.
TOR and paradigm change: cell growth is controlled.
Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Tuberous sclerosis complex: a brave new world?
mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression.
Fetal Primary Cardiac Tumors During Perinatal Period.
Energetic interventions for healthspan and resiliency with aging.
Geroprotectors as a therapeutic strategy for COPD - where are we now?
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Endovascular treatment of vasculogenic erectile dysfunction.
The therapeutic potential of mTOR inhibitors in breast cancer.
Targeting autophagy to sensitive glioma to temozolomide treatment.
mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
Searching for targets for the systemic therapy of mesothelioma.
Sirolimus--it doesn't deserve its bad Rap(a).
Emerging functions of autophagy in kidney transplantation.
Novel agents in gastroenteropancreatic neuroendocrine tumors.
Tolerance in liver transplantation: Biomarkers and clinical relevance.
Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases.
Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.
Immunosuppressive minimization with mTOR inhibitors and belatacept.
Calcineurin inhibitor-free protocols: risks and benefits.
Will kinase inhibitors make it as glioblastoma drugs?
Posttransplant anemia: the role of sirolimus.
Targeting the PI3K-AKT-mTOR signaling network in cancer.
Modeling new therapies for infantile spasms.
Sirolimus: a current perspective.
Clinical development of mTOR inhibitors in breast cancer.
Impact of genetic alterations on mTOR-targeted cancer therapy.
Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.
Fully bioresorbable drug-eluting coronary scaffolds: A review.
Current options for the treatment of facial angiofibromas.
Rapalogs in cancer prevention: anti-aging or anticancer?
mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?
Dysregulation of mTOR activity through LKB1 inactivation.
Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
Caloric restriction and chronic inflammatory diseases.
Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Systemic therapy for advanced pancreatic neuroendocrine tumors.